Respiratory Syncytial Virus (RSV) vaccines and monoclonal antibodies to protect infants, pregnant women, and adults. UPDATED JULY 2026: (1) GSK Arexvy label expanded to adults 18–49 at high risk (FDA, March 13, 2026); (2) CDC now recommends a single dose of RSV vaccine for all adults ≥75 and adults 50–74 at increased risk (updated guidance Feb 24, 2026); (3) all three RSV vaccines — Arexvy, Abrysvo, mResvia — are now FDA-approved across the 18–59 high-risk range and 60+. There is no CDC preference among the three products.
GSK Arexvy now approved for adults 18-49 years old at increased risk for severe RSV disease. This is a significant expansion from the previous 60+ age group.
Maternal vaccination provides passive protection to newborns during their first vulnerable months of life.
Due to late RSV season start, 48 jurisdictions extended infant immunization recommendations through April 30, 2026 (normally ends March 31). Check with your state health department.
#1
Leading cause of hospitalization in infants
17,000
RSV hospitalizations/year (with chronic conditions)
60,000-160,000
RSV hospitalizations/year in older adults
5-7 months
Typical RSV season (varies by region)
Last Updated: April 28, 2026
Major Update: GSK Arexvy age expansion to 18-49 years (March 13, 2026)
Information based on FDA approvals, CDC guidance, and manufacturer data as of April 2026